NCT01178697View on ClinicalTrials.gov

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

PHASE2UnknownINTERVENTIONAL
Timeline

Start Date

January 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

December 31, 2010

Conditions
Central Retinal Vein Occlusion
Interventions
DRUG

Bevasizumab

Intravitreal, 1.25 mg, 3 times, one month apart.

DRUG

Triamcinolone Acetonide

Intravitreal, 2 mg, 2 times, two months apart.

Trial Locations (1)

166666

RECRUITING

Imam Hossein medical center, Tehran

Sponsors
All Listed Sponsors
collaborator

Ophthalmic Research Center

AMBIG

lead

Shahid Beheshti University of Medical Sciences

OTHER